COVID-19 related olfactory dysfunction

Purpose of review This article reviews the literature on COVID-19 related anosmia, focusing on the epidemiology, pathophysiology recovery rates, current available treatment options, and research regarding novel treatments. Recent findings Loss of sense of smell is one of the most prevalent symptoms reported by patients after COVID-19 infection. Even though there is a high self-reported recovery rate, recent studies have demonstrated that up to 7% of the patients remain anosmic more than 12 months after onset, leaving millions worldwide with severe olfactory dysfunction. Olfactory training remains the first line recommended treatment. Given the paucity of effective medical treatments options researchers are exploring novel therapeutic options. Olfactory dysfunction remains a significant and persistent legacy of the COVID-19 pandemic, but heightened awareness may stimulate research that leads to the development of much-needed treatment options.

Automated summary

This article reviews the epidemiology, pathophysiology, recovery rates, current treatment options, and research on novel treatments for COVID-19 related anosmia. It is found that loss of sense of smell is a common symptom after COVID-19 infection, and some patients remain anosmic for more than 12 months. Olfactory training is recommended as the first line treatment option.